Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 3, 2010, Pages 174-177

  Conklin, Laurie S ^a   Cohen, Bernard ^b   Wilson, Lindsay ^c   Cuffari, Carmen ^c   Oliva Hemker, Maria ^c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b Division of Pediatric Hematology   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISOLONE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CASE REPORT; CROHN DISEASE; DERMATOLOGY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INJECTION SITE PRURITUS; LEUKOPENIA; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; RECURRENT DISEASE; SKIN BIOPSY; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; CROHN DISEASE; DRUG ERUPTIONS; EXANTHEMA; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; RISK ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 77749254887     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.7     Document Type: Article

References (31)

1. Rutgeerts, P., Vermeire, S. & Van Assche, G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136, 1182-1197 (2009).
2. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 354, 2462-2476 (2006).
3. Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: the ACCeNT I randomized trial. Lancet 359, 1541-1549 (2002).
4. Hyams, J. et al. Induction and maintenance Infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132, 863-873 (2007).
5. Eidelwein, A. P., Cuffari, C., Abadom, V. & Oliva-Hemker, M. Infliximab effiicacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11, 213-218 (2005).
6. Rosh, J. R. et al. Retrospective evaluation of the safety and effect of adalimumab therapy (ReSeAT) in pediatric Crohn's disease. Am. J. Gastroenterol. 104, 3042-3049 (2009).
7. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 17, 244-279 (2008).
8. Delle Sedie, A., Bazzichi, L., Bombardieri, S. & Riente, L. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand. J. Rheumatol. 36, 403-404 (2007).
9. Esmailzadeh, A. et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 219, 163-167 (2009).
10. Asarch, A. et al. Lichen-planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J. Am. Acad. Dermatol. 61, 104-111 (2009).
11. Wollina, U. et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am. J. Clin. Dermatol. 9, 1-14 (2008).
12. Aslanidis, S., Pyrpasopoulou, A., Douma, S. & Triantafyllou, A. Tumor necrosis factor-α antagonist-induced psoriasis: yet another paradox in medicine. Clin. Rheumatol. 27, 377-380 (2008).
13. Cohen, J. D. et al. Psoriasis induced by tumor necrosis factor-α antagonist therapy: a case series. J. Rheumatol. 34, 380-385 (2007).
14. Verea, M. M., Del Pozo, J., yebra-Pimentel, M. T., Porta, A. & Foseca, E. Psoriasiform eruption induced by infliximab. Ann. Pharmacother. 38, 54-57 (2004).
15. Sfikakis, P. P., Iliopoulos, A., elezoglou, A., Kittas, C. & Stratigos, A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthritis Rheum. 52, 2513-2518 (2005).
16. Goiriz, R., Daudén, E., Pérez-Gala, S., Guhl, G. & García-Díez, A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin. Exp. Dermatol. 32, 167-169 (2007).
17. Harrrison, M. J. et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68, 209-215 (2009).
18. Chaudhari, U. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357, 1842-1847 (2001).
19. FDA alert. Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira Cimzia, and Simponi) [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm (2009).
20. Fiorino, G., Allez, M., Malesci, A. & Danese, S. Review article: anti TNF-α induced psoriasis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29, 921-927 (2009).
21. Nestle, F. O., Kaplan, D. H. & Barker, J. Psoriasis N. Engl. J Med. 361, 496-509 (2009).
22. Ko, J. M., Gottlieb, A. B. & Kerbleski, J. F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatol. Treat. 20, 100-108 (2009).
23. Lee, F. I., Bellary, S. V. & Francis, C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am. J. Gastroenterol. 85, 962-963 (1990).
24. Collamer, A. N., Guerrero, K. T., Henning, J. S. & Battafarano, D. F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59, 996-1001 (2008).
25. Carter, J. D., Gerard, H. C. & Hudson, A. P. Psoriasiform lesions induced by tumor necrosis factor antagonists: a skin-deep medical conundrum. Ann. Rheum. Dis. 67, 1181-1183 (2008).
26. Palucka, A. K. et al. Cross-regulation of TNF and IFNα in autoimmune diseases. Proc. Natl Acad. Sci. USA 102, 3372-3377 (2005).
27. Cuchacovich, R., espinoza, C. G., Virk, Z. & Espinoza, L. R. Biologic therapy (TNF-α antagonists)-induced psoriasis: a cytokine imbalance between TNF-α and IFNα? J. Clin. Rheumatol. 14, 353-356 (2008).
28. Seneschal, J. et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br. J. Dermatol. 161, 1081-1088 (2009).
29. Michaelsson, G., Kajermo, U., Michaelsson, A. & Hagforsen, E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-α in the normal palmar eccrine sweat duct? Br. J. Dermatol. 153, 1220-1221 (2005).
30. Costa-Romero, M., Coto-Segura, P., Suarez-Saavedra, S., Ramos-Polo, E. & Santos-Juanes, J. Guttate psoriasis induced by Infliximab in a child with Crohn's disease. Inflamm. Bowel Dis. 14, 1462-1463 (2008).
31. Peek, R., Scott-Jupp, R., Strike, H., Clinch, J. & Ramanan, A. V. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann. Rheum. Dis. 65, 1259 (2006).